540 related articles for article (PubMed ID: 29107152)
1. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
[TBL] [Abstract][Full Text] [Related]
2. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
3. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales.
Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ
JHEP Rep; 2022 Oct; 4(10):100552. PubMed ID: 36119722
[TBL] [Abstract][Full Text] [Related]
4. Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study.
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
J Viral Hepat; 2018 May; 25(5):473-481. PubMed ID: 29194861
[TBL] [Abstract][Full Text] [Related]
5. Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study.
McDonald SA; Hutchinson SJ; Bird SM; Mills PR; Robertson C; Dillon JF; Williams T; Goldberg DJ
Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):49-57. PubMed ID: 19773667
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
7. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
Hutchinson SJ; Valerio H; McDonald SA; Yeung A; Pollock K; Smith S; Barclay S; Dillon JF; Fox R; Bramley P; Fraser A; Kennedy N; Gunson RN; Templeton K; Innes H; McLeod A; Weir A; Hayes PC; Goldberg D
Gut; 2020 Dec; 69(12):2223-2231. PubMed ID: 32217640
[TBL] [Abstract][Full Text] [Related]
8. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ
J Hepatol; 2015 Feb; 62(2):269-77. PubMed ID: 25200903
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025.
Rodríguez-Tajes S; Pocurull A; Castillo J; Casanova G; Vega L; Lens S; Mariño Z; Londoño MC; Forner A; Torres F; Forns X
J Hepatol; 2020 Dec; 73(6):1360-1367. PubMed ID: 32697948
[TBL] [Abstract][Full Text] [Related]
10. Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis.
McDonald SA; Innes HA; Aspinall EJ; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
Liver Int; 2018 Aug; 38(8):1402-1410. PubMed ID: 29288595
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness.
Innes HA; Hutchinson SJ; Barclay S; Cadzow E; Dillon JF; Fraser A; Goldberg DJ; Mills PR; McDonald SA; Morris J; Stanley A; Hayes P;
Hepatology; 2013 Feb; 57(2):451-60. PubMed ID: 22961861
[TBL] [Abstract][Full Text] [Related]
12. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.
Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ
J Hepatol; 2021 Feb; 74(2):293-302. PubMed ID: 32931879
[TBL] [Abstract][Full Text] [Related]
13. Alcohol use disorders and the risk of progression of liver disease in people with hepatitis C virus infection - a systematic review.
Llamosas-Falcón L; Shield KD; Gelovany M; Manthey J; Rehm J
Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):45. PubMed ID: 32605584
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
15. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
[TBL] [Abstract][Full Text] [Related]
16. Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
McDonald SA; Barclay ST; Innes HA; Fraser A; Hayes PC; Bathgate A; Dillon JF; Went A; Goldberg DJ; Hutchinson SJ
J Viral Hepat; 2021 Sep; 28(9):1246-1255. PubMed ID: 34002914
[TBL] [Abstract][Full Text] [Related]
17. Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection.
Forouzannia F; Hamadeh A; Passos-Castilho AM; Erman A; Yu A; Feng Z; Janjua NZ; Sander B; Greenaway C; Wong WWL
Liver Int; 2024 Jun; 44(6):1383-1395. PubMed ID: 38445848
[TBL] [Abstract][Full Text] [Related]
18. Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study.
Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ
Clin Infect Dis; 2021 Dec; 73(11):2037-2044. PubMed ID: 34107022
[TBL] [Abstract][Full Text] [Related]
19. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
[TBL] [Abstract][Full Text] [Related]
20. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
